Equillium, Inc. (EQ) Key Statistics & Financial Ratios

Equillium, Inc. (EQ) — Price $1.85 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Equillium, Inc. (EQ). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor.

Stock Data

Price$1.85
Market Cap$117M
Enterprise Value$60.7M
Beta1.74
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-8.00
Price / Book4.09
P/S0.00
EV/EBITDA-3.31
EV/Sales0.00
EV/FCF-3.02
P/FCF-6.45
Earnings Yield-8.68%
FCF Yield-17.13%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity-41.15%
Return on Assets-30.70%
Return on Invested Capital-34.10%
Return on Capital Employed-34.35%

Financial Health

Current Ratio23.40
Quick Ratio23.40
Cash Ratio23.07
Debt / Equity0.01
Debt / Assets1.00%
Net Debt / EBITDA3.08
Interest Coverage0.00

Per-Share Data

Revenue per share0.00
Book Value per share0.50
Cash per share0.51
FCF per share-0.18
Tangible Book Value per share0.50
Dividend per share0.00

Related companies: COEP · CUE · FBIO · IPSC · MDCX · NRXP · OSTX

Explore sector: Healthcare · Biotechnology

More sections of EQ: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks